AR021578A1 - Formulacion en perlas de pravastatina con revestimiento enterico - Google Patents

Formulacion en perlas de pravastatina con revestimiento enterico

Info

Publication number
AR021578A1
AR021578A1 ARP990106243A ARP990106243A AR021578A1 AR 021578 A1 AR021578 A1 AR 021578A1 AR P990106243 A ARP990106243 A AR P990106243A AR P990106243 A ARP990106243 A AR P990106243A AR 021578 A1 AR021578 A1 AR 021578A1
Authority
AR
Argentina
Prior art keywords
formulation
pravastatin
methacrylic acid
enteric coating
acid copolymer
Prior art date
Application number
ARP990106243A
Other languages
English (en)
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR021578A1 publication Critical patent/AR021578A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una formulacion en perlas de pravastatina con revestimiento entérico, la cual incluye pravastatina, opcionalmente un agente de basificacion tal como MgO oCaCO3, y un revestimiento entérico formado de un copolímero de ácido metacrílico el cual puedes er un copolímero de acrilato de metilo/ácido metacrílico o uncopolímero de metacrilato de metilo/ácido metacrílico, y plastificante tal como ftalato de dietilo y un espolvoreo de talco. La formulacion con revestimientoentérico tienen una buenaresist encia al deterioro en un pH menor que 3, pero tiene buenas propiedades de liberacion de fármaco en mayores que 4 y proporcionabiodisponibilidad incrementada y disminucion mejorada del LDL y los TGs comparado a las formulaciones depravastatina las cu ales no incluyen un revestimientoentérico y no proporcionan liberacion por todo el intestino delgado durante un tiempo de absorcion prolongado.
ARP990106243A 1998-12-07 1999-12-07 Formulacion en perlas de pravastatina con revestimiento enterico AR021578A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20654998A 1998-12-07 1998-12-07

Publications (1)

Publication Number Publication Date
AR021578A1 true AR021578A1 (es) 2002-07-24

Family

ID=22766876

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990106243A AR021578A1 (es) 1998-12-07 1999-12-07 Formulacion en perlas de pravastatina con revestimiento enterico

Country Status (3)

Country Link
AR (1) AR021578A1 (es)
AU (1) AU2161000A (es)
WO (1) WO2000033821A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
KR20020062340A (ko) * 1999-12-14 2002-07-25 비오갈 기오기스제르갸르 알티. 신규 형태의 프라바스타틴 나트륨
JP2005500307A (ja) 2001-06-21 2005-01-06 アンドルックス ファーマスーティカルズ インコーポレーテッド プラバスタチンを含む安定な徐放性薬剤組成物
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
EP1465605A1 (en) * 2002-01-11 2004-10-13 Athpharma Limited Pravastatin pharmaceutical formulations and methods of their use
EP1905431A1 (en) * 2002-01-11 2008-04-02 Circ Pharma Research and Development Limited Pravastatin pharmaceutical formulations and methods of their use
US20050089572A1 (en) * 2002-03-22 2005-04-28 Manoj Kumar Controlled release drug delivery system of pravastatin
PL375411A1 (en) * 2002-09-03 2005-11-28 Biovail Laboratories, Inc. Pharmaceuticals formulations and methods for modified release of statin drugs
US20040132806A1 (en) * 2002-09-03 2004-07-08 Jackie Butler Pravastatin pharmaceutical formulations and methods of their use
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
EP1802285B1 (en) 2004-10-21 2013-02-27 Aptalis Pharmatech, Inc. Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US20060105038A1 (en) * 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
DE102005032806A1 (de) * 2005-07-12 2007-01-18 Röhm Gmbh Verwendung eines teilneutralisierten, anionischen (Meth)acrylat-Copolymers als Überzug für die Herstellung einer Arzneiform mit einer Wirkstofffreisetzung bei erniedrigten pH-Werten
US20070092573A1 (en) * 2005-10-24 2007-04-26 Laxminarayan Joshi Stabilized extended release pharmaceutical compositions comprising a beta-adrenoreceptor antagonist
TWI471146B (zh) 2009-12-02 2015-02-01 Aptalis Pharma Ltd 菲索特芬那定（ｆｅｘｏｆｅｎａｄｉｎｅ）微膠囊及包含其之組合物
EP2343054A1 (en) 2010-01-04 2011-07-13 LEK Pharmaceuticals d.d. Pellets and microparticles of pravastatin sodium and a process of making them
EP3277274B1 (en) 2015-04-01 2024-06-12 Cedars-Sinai Medical Center Anti-methanogenic lovastatin analogs or derivatives and uses thereof
CN111803462A (zh) * 2020-07-15 2020-10-23 浙江诺得药业有限公司 一种普伐他汀钠肠溶片及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158777A (en) * 1990-02-16 1992-10-27 E. R. Squibb & Sons, Inc. Captopril formulation providing increased duration of activity
US5225202A (en) * 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions

Also Published As

Publication number Publication date
AU2161000A (en) 2000-06-26
WO2000033821A1 (en) 2000-06-15

Similar Documents

Publication Publication Date Title
AR021578A1 (es) Formulacion en perlas de pravastatina con revestimiento enterico
BR0109943A (pt) Composições farmacêuticas
AR027091A1 (es) Forma de dosificacion de farmacos accionada por un hidrogel
ATE391496T1 (de) Geschmacksmaskierte pharmazeutische formulierungen
CO5580776A2 (es) Formulacion farmaceutica estable en solucion de oxaliplatino
ATE349207T1 (de) Verstärkte wirkung mehrfach ungesättigter fettsäuren
IL157741A0 (en) Pharmaceutical compositions containing an antihyperplastic active agent
RS56252B1 (sr) Jednodnevne formulacije oksikodona
NO20015502L (no) Sulfonamid- og sulfamidsubstituerte imidazokinoliner
PH12017502416A1 (en) 17-hydroxyprogesterone ester-containing oral compositions and related methods
ATE422350T1 (de) Anisinsäure und glyceride enthaltende zusammensetzungen
HK1077023A1 (en) Spheroids, preparation method thereof and pharmaceutical compositions
WO2005009410A3 (en) Pharmaceutical compositions having a swellable coating
BR0312782A (pt) Composição para o tratamento de manchas
AR021934A1 (es) Composicion de administracion oral con liberacion controlada de al menos un analgesico
EA200300110A1 (ru) Композиция элетриптана в виде частиц
MXPA03003741A (es) Metodos y composiciones para el tratamiento de enfermedades oftalmicas.
ES2180729T3 (es) Tratamiento terapeutico combinado de las patologias hiperproliferantes.
MXPA04003540A (es) Utilizacion de un copolimero para producir una forma galenica que contiene un peptido o proteina como agente activo.
IL157649A0 (en) Adenosine derivatives having an acetylene group in the 4' position, pharmaceutical compositions containing them and use thereof in decreasing plasma free fatty acid concentration
TW200509863A (en) Irradiation device for medical use
PE20050441A1 (es) Composiciones antibioticas
SE0001916D0 (sv) Novel formulation
ECSP993228A (es) Formulacion de perlas de pravastatina con revestimiento enterico
DE50204203D1 (de) Orale fludara reinst formulierung mit schneller freisetzung des wirkstoffes